Tom Swegle is a serial entrepreneur who chases opportunities. Tom is focused on investing, developing and launching business entities that build value for within the prescription and over-the-counter biopharmaceutical and life sciences sectors. Such companies include clinical pharmaceutical organizations, e-commerce pet medications, and medical marijuana.

Tom has been a partner and CEO for biopharmaceutical institutions such as RegenaCorp and MedCara Pharmaceuticals. Throughout his career, Tom has worked with companies pushing the envelopes of science, technology, and commercial strategy from products developed from the bench of compounding pharmacies. In addition, Tom has invested in and/or worked for entrepreneurial companies such as VetCara, NuCara Management Group, Paragon Manufacturing, John Deere Health, and The Meyocks Group.

Most recently, Tom has successfully developed and implemented a compounding prescription model to dispense products such as Med101 under the brand name WartPEEL®, a topical prescription treatment for resistant warts. This has resulted in the creation of marketing and pharmacy operations, distribution, reimbursement strategies and supporting infrastructures for the Med101 therapy, thus gaining valuable anecdotal patient feedback and revenue streams.

In the past, Tom has successfully established multiple collaborations within the dermatological and dental prescription and OTC markets. Tom’s expertise is not restricted to biopharmaceutical advisory services, as he has led the successful completion of multiple projects focused on market and healthcare industries.

Tom has over 10 years of pharmaceutical executive experience that has involved the direction, preparation and implementation of out-licensing and partner materials, including: investor briefing documents, financial and valuation models, market scaling, intellectual property, clinical and regulatory data. In addition, Tom has successfully negotiated with the FDA to approve pre-clinical data and received approval to begin Phase I human studies and filing for Med101. Tom has directed the consultant services in preparing, filing, and otherwise advising in the preparation and filing of INDs, Supplemental NDAs, NDAs, investigational brochures, labeling, orphan applications, and Investigator INDs; negotiating with FDA on pre-IND, end of phase I-II, pre-NDA meetings; resolution of clinical hold and general issues.

Tom Swegle is classically trained in business development and has honed his expertise while stewarding some of the highest profiled brands in the World. Over the past 20 years, Tom has contributed to the continued success of demonstrating value through strategic branding and market planning.

A Fortune 150 Executive and Marketing Leader: Tom received a “Gold” acknowledgement for healthcare branding by the National Healthcare Marketing Report. Tom has been fortunate to enjoy a diverse marketing and management career that has included key positions with well-known firms and brands including John Deere.

Entrepreneurial by nature, Tom has more than two decades of experience in start-ups and turnaround management: Over the past 20 years he has been utilizing marketing experience in building communication programs with small and midsize businesses. Tom has a solid track record of increasing brand equity, reducing costs, and streamlining communications in a wide range of situations.

Skilled in all areas of marketing management with richly varied communication experience. Tom has a record of exceeding company objectives achieving double-digit gains in awareness, revenues, and profits. Successful in developing product expansion throughout the U.S. and worldwide, building premier distribution networks, creating innovative advertising, and expanding into new industries and markets.